Cherian Karunapuzha, MD
Neurology · Oklahoma City, OKNPI 1881896397
Payments from drug & device makers
Across 4,463 payments — averaging $926.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$1.1M
- Neurocrine Biosciences, Inc.$703K
- MDD US Operations, LLC$656K
- Acadia Pharmaceuticals Inc$475K
- Amneal Pharmaceuticals LLC$409K
- Kyowa Kirin, Inc.$299K
- plus $497K from 37 others
What the payments were for
- Consulting fees$300,3007%
- Speaking & faculty fees$3,256,85379%
- Travel & lodging$501,46112%
- Food & beverage$76,2592%
- Education$1,8950%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,136,768 in reported general payments places this provider in the 95th percentile of 152 neurology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 539 | $2,753,523 |
| Austedo XrDeutetrabenazine | 181 | $2,252,490 |
| AustedoDeutetrabenazine | 192 | $2,090,522 |
| IngrezzaValbenazine Tosylate | 177 | $1,714,585 |
| RytaryCarbidopa/Levodopa | 877 | $1,239,936 |
| GocovriAmantadine Hcl | 297 | $1,024,007 |
| NourianzIstradefylline | 199 | $449,711 |
| InbrijaLevodopa | 24 | $106,838 |
| Droxidopa | 93 | $86,140 |
| OngentysOpicapone | 75 | $80,832 |
| XadagoSafinamide Mesylate | 43 | $64,516 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 1,753 | $57,482 |
| HorizantGabapentin Enacarbil | 47 | $52,136 |
| AmantadineAmantadine Hcl | 611 | $32,922 |
| MyrbetriqMirabegron | 51 | $27,698 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo | $1,097,766 | $4,343,013373 claims |
| Acadia Pharmaceuticals IncNuplazid | $474,658 | $2,753,523539 claims |
| Neurocrine Biosciences, Inc.Ingrezza, Ongentys | $703,004 | $1,795,417252 claims |
| Amneal Pharmaceuticals LLCRytary, Crexont | $408,968 | $1,254,471894 claims |
| MDD US Operations, LLCGocovri | $656,351 | $1,024,007297 claims |
| Kyowa Kirin, Inc.Nourianz | $299,186 | $449,711199 claims |
| Acorda Therapeutics, IncInbrija | $89,680 | $106,83824 claims |
| Arbor Pharmaceuticals, Inc.Horizant | $50 | $52,13647 claims |
| UCB, Inc.Neupro | $11 | $25,02218 claims |
| AbbVieLinzess | $185,796 | $13,09022 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 152 neurology providers in Oklahoma.
Other neurology in Oklahoma City
- Gabriel PardoOklahoma City$10.3M
- James BattisteOklahoma City$1.1M
- Mariana VargaOklahoma City$670K
- Marguerite ButcheeOklahoma City$324K
- Chelsea BerkleyOklahoma City$277K
- Evgeny SidorovOklahoma City$212K
- Aaron FarrowOklahoma City$172K
- Ashish MasihOklahoma City$168K
- Erika Santos HortaOklahoma City$93K
- Christi PendergraftOklahoma City$73K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.